Wright M R, Rurak D W, van der Weyde M P, Taylor S M, Axelson J E
Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
J Pharmacol Exp Ther. 1991 Sep;258(3):897-902.
The disposition of the beta-2 adrenoreceptor agonist, ritodrine, has been examined in the fetal lamb during and after constant rate fetal intravenous infusion (8-24 h). Samples were collected from the fetal femoral artery, umbilical vein, maternal femoral artery, uterine vein, fetal trachea and the amniotic activity for ritodrine quantitation. The amniotic fluid was also analyzed for conjugated metabolites of ritodrine. Ritodrine appears to be cleared across the sheep placenta only to a limited extent (placental clearance 9.2 +/- 2 ml/min/kg; mean +/- S.E.M.). There is, however, significant fetal nonplacental clearance of ritodrine (fetal nonplacental clearance 52.8 +/- 8.0 ml/min/kg). At least part of this clearance appears to be due to fetal drug metabolism, as evidenced by the accumulation of glucuronide conjugates of ritodrine in the amniotic fluid. Ritodrine was also shown to accumulate in the amniotic and fetal tracheal fluids and persist after fetal arterial plasma ritodrine concentrations became undetectable. The accumulation of ritodrine in the tracheal fluid may be of pharmacologic significance, given the well documented, potent effects of beta-2 agonists on fetal lung function and development.
在胎儿恒速静脉输注(8 - 24小时)期间及之后,对胎羊体内β - 2肾上腺素能受体激动剂利托君的处置情况进行了研究。从胎儿股动脉、脐静脉、母体股动脉、子宫静脉、胎儿气管采集样本,并分析羊水活性以定量利托君。还对羊水进行了利托君结合代谢物的分析。利托君似乎仅在有限程度上通过绵羊胎盘清除(胎盘清除率9.2±2毫升/分钟/千克;平均值±标准误)。然而,利托君在胎儿体内存在显著的非胎盘清除(胎儿非胎盘清除率52.8±8.0毫升/分钟/千克)。至少部分这种清除似乎是由于胎儿药物代谢,利托君葡萄糖醛酸结合物在羊水中的积累证明了这一点。利托君还被证明在羊水和胎儿气管液中积累,并且在胎儿动脉血浆中利托君浓度变得无法检测后仍持续存在。鉴于β - 2激动剂对胎儿肺功能和发育有充分记录的强效作用,利托君在气管液中的积累可能具有药理学意义。